Bionovate Net Income Applicable To Common Shares from 2010 to 2026
| BIIO Stock | USD 0.0001 0.00 0.00% |
Net Loss | First Reported 2016-06-30 | Previous Quarter -19.6 K | Current Value -21.6 K | Quarterly Volatility 66.4 K |
Check Bionovate Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bionovate Technologies' main balance sheet or income statement drivers, such as Interest Expense of 36.9 K, Selling General Administrative of 54.3 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 3.87. Bionovate financial statements analysis is a perfect complement when working with Bionovate Technologies Valuation or Volatility modules.
Bionovate | Net Income Applicable To Common Shares | Build AI portfolio with Bionovate Stock |
Evaluating Bionovate Technologies's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Bionovate Technologies Corp's fundamental strength.
Latest Bionovate Technologies' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Bionovate Technologies Corp over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Bionovate Technologies' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bionovate Technologies' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Bionovate Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (209,685) | |
| Coefficient Of Variation | (190.65) | |
| Mean Deviation | 193,492 | |
| Median | (106,544) | |
| Standard Deviation | 399,762 | |
| Sample Variance | 159.8B | |
| Range | 1.7M | |
| R-Value | 0.04 | |
| Mean Square Error | 170.2B | |
| R-Squared | 0 | |
| Significance | 0.88 | |
| Slope | 3,088 | |
| Total Sum of Squares | 2.6T |
Bionovate Net Income Applicable To Common Shares History
About Bionovate Technologies Financial Statements
Bionovate Technologies investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Bionovate Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -95.9 K | -100.7 K |
Pair Trading with Bionovate Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionovate Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionovate Technologies will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Bionovate Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionovate Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionovate Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionovate Technologies Corp to buy it.
The correlation of Bionovate Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionovate Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionovate Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionovate Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Bionovate Technologies Correlation against competitors. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Health Care Equipment & Supplies sector continue expanding? Could Bionovate diversify its offerings? Factors like these will boost the valuation of Bionovate Technologies. Projected growth potential of Bionovate fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bionovate Technologies data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Bionovate Technologies's market price often diverges from its book value, the accounting figure shown on Bionovate's balance sheet. Smart investors calculate Bionovate Technologies' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Bionovate Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bionovate Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bionovate Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bionovate Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.